Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (±)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI)

Neuropsychopharmacology

Volumn 28, Issue 2, 2003, Pages 244-252

  Qu, Ying ^a   Chang, Lisa ^a   Klaff, Justin ^a   Balbo, Andrea ^a   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Arachidonic acid; Brain; DOI; Imaging; Mianserin; Phospholipase A2; Serotonin (5 HT)

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; PHOSPHOLIPASE A; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR;

ANIMAL; ARTICLE; AUTORADIOGRAPHY; BRAIN; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FISCHER 344 RAT; MALE; METABOLISM; PHYSIOLOGY; RAT; WAKEFULNESS;

AMPHETAMINES; ANIMALS; AUTORADIOGRAPHY; BRAIN; ENZYME ACTIVATION; MALE; PHOSPHOLIPASES A; RATS; RATS, INBRED F344; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; WAKEFULNESS;

EID: 0037311168     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300022     Document Type: Article

References (100)

1. Anji A, Kumari M, Sullivan Hanley NR, Bryan GL, Hensler JG (2000). Regulation of 5-HT2A receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin. Neuropharmacology39: 1996-2005.
2. Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB (1990). Autoradiographic characterization of (+)-1- (2,5-dimethoxy-4-[125I]iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1C receptors in rat brain. J Pharmacol Exp Ther 255: 843-857.
3. Arvidsson LE, Hacksell U, Glennon RA (1986). Recent advances in central 5-hydroxytryptamine receptor agonists and antagonists. Prog Drug Res30: 365-471.
4. Ashby Jr CR, Jiang LH, Kasser RJ, Wang RY (1990). Electrophysiological characterization of 5-hydroxytryptamine2 receptors in the rat medial prefrontal cortex. J Pharmacol Exp Ther252: 171-178.
5. Axelrod J (1995). Phospholipase A2 and G proteins. Trends Neurosci18: 64-65.
6. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology38: 1083-1152.
7. Bayon Y, Hernandez M, Alonso A, Nunez L, Garcia-Sancho J, Leslie C et al(1997). Cytosolic phospholipase A2 is coupled to muscarinic receptors in the human astrocytoma cell line 1321N1: characterization of the transducing mechanism. Biochem J 323: 281-287.
8. Berendsen HH, Broekkamp CL (1991). Attenuation of 5-HT1A and 5-HT2 but not 5-HT1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or anti-depressants. Psychopharmacology (Berl)105: 219-224.
9. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clark WP (1998). Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol54: 94-104.
10. Blackshear MA, Sanders-Bush E (1982). Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther221: 303-308.
11. Bloom FE (1985). CNS plasticity: a survey of opportunities. In: Bignami A, Bolis CL, Bloom FE, Adeloye A (eds). Central Nervous System Plasticity and Repair. Raven Press: New York, pp 3-11.
12. Breier A (1995). Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res14: 187-202.
13. Brooks RC, McCarthy KD, Lapetina EG, Morell P (1989). Receptor stimulated phospholipase A2 activation is coupled to influx of external calcium and not to mobilization of intracellular calcium in C62B glioma cells. J Biol Chem264: 20147-20153.
14. Chang MCJ, Arai T, Freed LM, Wakabayashi S, Channing MA, Dunn BB et al(1997). Brain incorporation of [1-nC]-arachido-nate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. Brain Res755: 74-83.
15. Conn PJ, Sanders-Bush E (1986a). Agonist-induced phospho-inositide hydrolysis in choroid plexus. J Neurochem47: 1754-1760.
16. Conn PJ, Sanders-Bush E (1986b). Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J Neurosci 6: 3669-3675.
17. Cooper JR, Bloom FE, Roth RH (1996). The Biochemical Basis of Neuropharmacology. 7th edn. Oxford University Press: Oxford.
18. DeGeorge JJ, Nariai T, Yamazaki S, Williams WM, Rapoport SI (1991). Arecoline-stimulated brain incorporation of intravenously administered fatty acids in unanesthetized rats. J Neurochem56: 352-355.
19. DeGeorge JJ, Noronha JG, Bell JM, Robinson P, Rapoport SI (1989). Intravenous injection of [1-14C]arachidonate to examine regional brain lipid metabolism in unanesthetized rats. J Neurosci Res24: 413-423.
20. Dijcks FA, Ruigt GS, de Graaf JS (1991). Antidepressants affect amine modulation of neurotransmission in the rat hippocampal slice: II. Acute effects. Neuropharmacology30: 1151-1158.
21. Dunnett C (1964). New tables for multiple comparisons with a control. Biometrics20: 484-491.
22. Edagawa Y, Saito H, Abe K (2000). The serotonin 5-HT2 receptor-phospholipase C system inhibits the induction of long-term potentiation in the rat visual cortex. Eur J Neurosci12: 1391-1396.
23. Essom CR, Nemeroff CB (1996). Treatment of depression in adulthood. In: Shulman KI, Tohen M, Kutcher SP (eds). Mood Disorders across the Life Span. John Wiley: New York, pp 251-264.
24. Felder CC, Kanterman RY, Ma AL, Axelrod J (1990). Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc Natl Acad Sci USA87: 2187-2191.
25. Feuerstein TJ, Gleichauf O, Landwehrmeyer GB (1996). Modulation of cortical acetylcholine release by serotonin: The role of substance P interneurons. Naunyn Schmiedebergs Arch Pharmacol354: 618-626.
26. Fisone G, Snyder GL, Aperia A, Greengard P (1998). Na+, K+-ATPase phosphorylation in the choroid plexus: synergistic regulation by serotonin/protein kinase C and isoproterenol/ cAMP-PK/PP-1 pathways. Mol Med4: 258-265.
27. Fisone G, Snyder GL, Fryckstedt J, Caplan MJ, Aperia A, Greengard P (1995). Na+K+-ATPase in the choroid plexus. Regulation by serotonin/protein kinase C pathway. J Biol Chem270: 2427-2430.
28. Folch J, Lees M, Sloane Stanley GH (1957). A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem226: 497-509.
29. Fonlupt P, Croset M, Lagarde M (1994). Incorporation of arachidonic and docosahexaenoic acids into phospholipids of rat brain membranes. Neurosci Lett171: 137-141.
30. Frazer A, Offord SJ, Lucki I (1988). Regulation of serotonin receptors and responsiveness in the brain. In: Sanders-Bush E (ed). The Serotonin Receptors. Humana Press: New Jersey, pp 319-362.
31. Freo U, Holloway HW, Kalogeras K, Rapoport SI, Soncrant TT (1992). Adrenalectomy or metyrapone-pretreatment abolishes cerebral metabolic responses to the serotonin agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the hippocampus. Brain Res586: 256-264.
32. Freo U, Soncrant TT, Holloway HW, Rapoport SI (1991). Dose-and time-dependent effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a serotonergic 5-HT2 receptor agonist, on local cerebral glucose metabolism. Brain Res541: 63-69.
33. Gaggi R, Dall’Olio R, Roncada P (1997). Effect of the selective 5-HT receptor agonists 8-OHDPAT and DOI on behavior and brain biogenic amines of rats. Gen Pharmacol28: 583-587.
34. Giovacchini G, Chang MC, Bokde A, Connolly C, Channing MA, Herscovitch P et al(2001). Brain incorporation of [nC]arachi-donic acid (AA) and palmitic acid (PA). Human studies with PET (Abstract). J Nucl Med42(Suppl): 65P.
35. Glennon RA (1986). Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane (DOI). Life Sci39: 825-830.
36. Glennon RA (1987). Central serotonin receptors as targets for drug research. J Med Chem30: 1-12.
37. Gobert A, Millan MJ (1999). Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely moving rats. Neuropharmacology38: 315-317.
38. Grange E, Rabin O, Bell J, Rapoport SI, Chang MCJ (1998). Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res23: 1251-1257.
39. Hartman IV JL, Northup JK (1996). Functional reconstitution in situ of 5-hydroxytryptamine2c (5HT2c) receptors with aq and inverse agonism of 5HT2c receptor agonists. J Biol Chem271: 22591-22597.
40. Hayakawa T, Chang CJ, Rapoport SI, Appel NM (2001). Selective dopamine receptor stimulation differentially affects [3H]arachi-donic acid incorporation, a surrogate marker for phospholipase A2-mediated signal transduction, in a rodent model of Parkinson’s disease. J Pharmacol Exp Ther296: 1074-1084.
41. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al(1995). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev46: 157-203.
42. Ichikawa J, Meltzer HY (1995). DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res 698: 204-208.
43. Johnson RG, Stevens KE, Rose GM (1998). 5-Hydroxytryptamine-2 receptors modulate auditory filtering in the rat. J Pharmacol Exp Ther285: 643-650.
44. Jones CR, Arai T, Bell JM, Rapoport SI (1996). Preferential in vivo incorporation of [3H]arachidonic acid from blood into rat brain synaptosomal fractions before and after cholinergic stimulation. J Neurochem67: 822-829.
45. Kaufman MJ, Hartig PR, Hoffman BJ (1995). Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus. J Neurochem64: 199-205.
46. Kreiss DS, Lucki I (1995). Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther274: 866-876.
47. Leysen JE, Gommeren W, Janssen PF, Van Gompel P, Janssen PA (1988). Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation. Psychopharmacol Ser5: 12-26.
48. Li Q, Ma L, William K, Murphy DL (2001). 5-HT2A and 5-HT2C receptors are differently regulated in 5-HT transporter mice: Studies on the density and gene expression of the receptors. Soc Neurosci Abstr 26: 380.5.
49. Lira A, Bradley-Moore M, Zhou M, Fairhurst S, Menzaghi F, Brunner D et al(2001). Cognitive performance in 5-HT2A receptor knockout mice. Soc Neurosci Abstr27: 3804.
50. Liu R, Jolas T, Aghajanian G (2000). Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res87: 34-45.
51. Maiese K, Holloway HH, Larson DM, Soncrant TT (1994). Effect of acute and chronic arecoline treatment on cerebral metabolism and blood flow in the conscious rat. Brain Res28: 65-75.
52. Marcoli M, Rosu C, Bonfanti A, Raiteri M, Maura G (2001). Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers. J Pharmacol Exp Ther299: 1106-1111.
53. Mazzola-Pomietto P, Aulakh CS, Tolliver T, Murphy DL (1997). Functional subsensitivity of 5-HT2A and 5-HT2C receptors mediating hyperthermia following acute and chronic treatment with 5-HT2A/2C receptor antagonists. Psychopharmacology (Berl)130: 144-151.
54. 125I]LSD and [125I]DOI, a new psychotomimetic radioligand. Brain Res476: 45-56.
55. McKenna DJ, Peroutka SJ (1989). Differentiation of 5-hydroxy-tryptamine-2 receptor subtypes using 125I-R-(—)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin. J Neurosci9: 3482-3490.
56. Mills KC (1997). Serotonin syndrome. A clinical update. Crit Care Clin13: 763-783.
57. Morilak DA, Garlow SJ, Ciaranello RD (1993). Immunocytochem-ical localization and description of neurons expressing serotonin-2 receptors in rat brain. Neuroscience54: 701-717.
58. Nariai T, DeGeorge JJ, Lamour Y, Rapoport SI (1991). In vivo brain incorporation of [1-14C]arachidonate in awake rats, with or without cholinergic stimulation, following unilateral lesioning of nucleus basalis magnocellularis. Brain Res559: 1-9.
59. Orzi F, Diana G, Casamenti F, Palombo E, Fieschi C (1988). Local cerebral glucose utilization following unilateral and bilateral lesions of the nucleus basalis magnocellularis in the rat. Brain Res462: 99-103.
60. Osmundsen H, Hovik R (1988). b-Oxidation of polyunsaturated fatty acids. Biochem Soc Trans16: 420-422.
61. Ozawa H, Katamura Y, Hatta S, Amemiya N, Saito T, Ohshika H et al(1994). Antidepressants directly influence in situ binding of guanine nucleotide in synaptic membrane. Life Sci54: 925-932.
62. Pardridge WM, Mietus LJ (1980). Palmitate and cholesterol transport through the blood-brain barrier. J Neurochem 34: 463-466.
63. Paxinos G, Watson C (1987). The Rat Brain in Stereotaxic Coordinates. 3rd edn. Academic Press: New York.
64. Pazos A, Palacios JM (1985). Quantitative autoradiographic mapping of serotonin receptor in the rat brain: I. Serotonin-1 receptors. Brain Res346: 205-230.
65. PDSP Drug Database (2000). Psychoactive Drug Screening Program drug database (available at http://pdsp.cwru.edu/ pdsp.asp) (see also description in Hot picks: Psychopharmacokinetics unbound. Science 287: 543c).
66. Pinder RM (1985). Adrenoreceptor interactions of the enantiomers and metabolites of mianserin: are they responsible for the antidepressant effect?Acta Psychiatr Scand Suppl320: 1-9.
67. Pranzatelli MR (1990). Evidence for involvement of 5-HT2 and 5-HT1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI). Neurosci Lett115: 74-80.
68. Purdon AD, Rapoport SI (1998). Energy requirements for two aspects of phospholipid metabolism in mammalian brain. Biochem J335: 313-318.
69. Qu Y, Chang L, Klaff J, Balbo A, Rapoport SI (2001). Imaging phospholipase A2 mediated signal transduction in response to a 5-HT2 agonist in brain of awake rats (Abstract). J Neurochem78 (Suppl 1): 144.
70. Ramasubbu R, Ravindran A, Lapierre Y (2000). Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry33: 236-238.
71. Rapoport SI (1976). Blood-Brain Barrier in Physiology and Medicine. Raven Press: New York.
72. Rapoport SI (2001). In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci 16: 243-261, 279-284.
73. Rapoport SI, Chang MCJ, Spector AA (2001). Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res42: 678-685.
74. Rauser L, Savage JE, Meltzer HY, Roth BL (2001). Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther299: 83-89.
75. Reivich M (1974). Blood flow metabolism couple in brain. Res Publ Assoc Res Nerv Ment Dis53: 125-140.
76. Reynolds GP (2001). Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective. Expert Opin Pharmacother2: 543-548.
77. Robinson PJ, Noronha J, DeGeorge JJ, Freed LM, Nariai T, Rapoport SI (1992). A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Res Rev17: 187-214.
78. Robinson PJ, Rapoport SI (1986). Kinetics of protein binding determine rates of uptake of drugs by brain. Am J Physiol251: R1212-R1220.
79. Rocha B, Rigo M, Di Scala G, Sandner G, Hoyer D (1994). Chronic mianserin or eltoprazine treatment in rats: Effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels. Eur J Pharmacol262: 125-131.
80. Roth BL, Ciaranello RD (1991). Chronic mianserin treatment decreases 5-HT2 binding without altering 5-HT2 receptor mRNA. Eur J Pharmacol207: 169-172.
81. Roth BL, Kroeze WK, Patel S, Lopez E (2000). The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?Neuroscientist6: 252-262.
82. Sanders-Bush E, Breeding M, Roznoski M (1987). 5-HT2 binding sites after mianserin: comparison of loss of sites and brain levels of drug. Eur J Pharmacol133: 199-204.
83. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995). (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-in-duced head-twitches in the rat are mediated by 5-hydroxy-tryptamine (5-HT) 2A receptors: Modulation by novel 5-HT2A/2C antagonists, D1antagonists and 5-HT1A agonists. J Pharmacol Exp Ther273: 101-112.
84. Shimizu T, Wolfe LS (1990). Arachidonic acid cascade and signal transduction. J Neurochem55: 1-15.
85. Sokoloff L (1999). Energetics of functional activation in neural tissues. Neurochem Res24: 321-329.
86. Soncrant TT, Holloway HW, Rapoport SI (1985). Arecoline-induced elevations of regional cerebral metabolism in the conscious rat. Brain Res347: 205-216.
87. Sternbach H (1991). The serotonin syndrome. Am J Psychiatry148: 705-713.
88. Svenson A, Holmer E, Andersson LO (1974). A new method for the measurement of dissociation rates for complexes between small ligands and proteins as applied to the palmitate and bilirubin complexes with serum albumin. Biochim Biophys Acta342: 54-59.
89. Thase ME (2002). What role do atypical antipsychotic drugs have in treatment-resistant depression?J Clin Psychiatry63: 95-103.
90. Tournois C, Mutel V, Manivet P, Launay JM, Kellermann O (1998). Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line: involvement of arachidonic acid metabolism. J Biol Chem273: 17498-17503.
91. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS (2001). 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci21: 3572-3579.
92. Vial D, Piomelli D (1995). Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonic-specific phospholipase A2. J Neurochem64: 2765-2772.
93. Vijayaraghavan S, Huang B, Blumenthal EM, Berg DK (1995). Arachidonic acid as a possible negative feedback inhibitor of nicotinic acetylcholine receptors on neurons. J Neurosci15: 3679-3687.
94. Washizaki K, Purdon AD, DeGeorge JJ, Robinson PJ, Rapoport SI, Smith QR (1991). Fatty acid uptake and esterification by the in situ perfused rat brain. Soc Neuroscience Abstr17: 864.
95. Washizaki K, Smith QR, Rapoport SI, Purdon AD (1994). Brain arachidonic acid incorporation and precursor pool specific activity during intravenous infusion of unesterified [3H]arachi-donate in the anesthetized rat. J Neurochem63: 727-736.
96. Westphal RS, Backstrom JR, Sanders-Bush E (1995). Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanied agonist-mediated desensitization. Mol Pharmaco l48: 200-205.
97. Wettstein JG, Host M, Hitchcock JM (1999). Selectivity of action of typical and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2-amino-propane (DOI). Prog Neuropsychopharmacol Biol Psychiatry23: 533-544.
98. Wolf WA, Schutz LJ (1997). The serotonin 5-HT2C receptors is a prominent serotonin receptor in the basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J Neurochem69: 1449-1458.
99. Wooten GF, Collins RC (1981). Metabolic effects of unilateral lesion of the substantia nigra. J Neurosci1: 285-291.
100. Yamazaki S, DeGeorge JJ, Bell JM, Rapoport SI (1994). Effect of pentobarbital on incorporation of plasma palmitate into rat brain. Anesthesiology80: 151-158.